Literature DB >> 8392311

Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.

M A Slavin1, R R Bindra, C A Gleaves, M B Pettinger, R A Bowden.   

Abstract

Cytomegalovirus (CMV) often persists in the lungs of marrow transplant patients with CMV pneumonia, despite ganciclovir (GCV) treatment. To determine whether GCV resistance contributes to viral persistence, the susceptibilities of CMV isolates from diagnostic bronchoalveolar lavage samples and CMV isolates obtained during treatment or from autopsy lung tissue from 12 patients were compared by DNA hybridization. Resistance (50% effective dose, > 12 microM) was detected in an isolate from only one patient who had also received several courses of GCV. GCV resistance did not explain the persistence of CMV in the lung.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392311      PMCID: PMC187966          DOI: 10.1128/AAC.37.6.1360

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Quantification of cytomegalovirus in bronchoalveolar lavage fluid after allogeneic marrow transplantation by centrifugation culture.

Authors:  M A Slavin; C A Gleaves; H G Schoch; R A Bowden
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

2.  Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures.

Authors:  J M Pepin; F Simon; A Dussault; G Collin; M C Dazza; F Brun-Vezinet
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

3.  Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.

Authors:  J D Meyers; E C Reed; D H Shepp; M Thornquist; P S Dandliker; C A Vicary; N Flournoy; L E Kirk; J H Kersey; E D Thomas
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

4.  Antiviral activity of FIAU (1-[2'deoxy-2'-fluoro-1-beta-D-arabinofuranosyl]-5-iodo-uridine) on strains of cytomegalovirus sensitive and resistant to ganciclovir.

Authors:  W L Drew; R Miner; D King
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

5.  Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.

Authors:  W R Drobyski; K K Knox; D R Carrigan; R C Ash
Journal:  Transplantation       Date:  1991-07       Impact factor: 4.939

6.  Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens.

Authors:  S W Chou
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

7.  Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine.

Authors:  S A Plotkin; W L Drew; D Felsenstein; M S Hirsch
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

8.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Authors:  S C Stanat; J E Reardon; A Erice; M C Jordan; W L Drew; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus.

Authors:  W M Dankner; D Scholl; S C Stanat; M Martin; R L Sonke; S A Spector
Journal:  J Virol Methods       Date:  1990-06       Impact factor: 2.014

10.  Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia.

Authors:  D H Shepp; P S Dandliker; P de Miranda; T C Burnette; D M Cederberg; L E Kirk; J D Meyers
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

View more
  8 in total

Review 1.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

2.  How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

Authors:  Firas El Chaer; Dimpy P Shah; Roy F Chemaly
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

3.  Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.

Authors:  C Gilbert; J Roy; R Belanger; R Delage; C Beliveau; C Demers; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.

Authors:  Hisashi Gondo; Daisuke Himeji; Kenjiro Kamezaki; Akihiko Numata; Tetsuya Tanimoto; Ken Takase; Kenichi Aoki; Hideho Henzan; Koji Nagafuji; Toshihiro Miyamoto; Fumihiko Ishikawa; Kazuya Shimoda; Shuichi Inaba; Hiroshi Tsukamoto; Takahiko Horiuchi; Hitoshi Nakashima; Takeshi Otsuka; Koji Kato; Mika Kuroiwa; Masakazu Higuchi; Tsunefumi Shibuya; Tomohiko Kamimura; Kiyotaka Kuzushima; Tatsuya Tsurumi; Yoshinobu Kanda; Mine Harada
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

Review 5.  Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Authors:  Ellen Meijer; Greet J Boland; Leo F Verdonck
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 6.  Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Authors:  Nancy Perrottet; Laurent A Decosterd; Pascal Meylan; Manuel Pascual; Jerome Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

8.  High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation.

Authors:  R Nakamura; K Cortez; S Solomon; M Battiwalla; V J Gill; N Hensel; R Childs; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.